Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the two phase 3, 29-day, randomized, controlled reveal trials
Journal of the American Academy of Dermatology Feb 09, 2018
Stein-Gold L, et al. - Among patients with moderate to severe persistent erythema of rosacea, researchers investigated the efficacy of topical oxymetazoline cream 1.0%. Authors found that the moderate to severe persistent facial erythema of rosacea was effectively reduced by oxymetazoline. It was found to be well tolerated.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
